Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency
| Autor: | Vincent F.M. Segers, Jhana O. Hendrickx, Hadis Shakeri, Jente R A Boen, Sofie De Moudt, Arthur J. A. Leloup, Pieter-Jan Guns, Griet Jacobs, Guido R.Y. De Meyer, Gilles W. De Keulenaer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Endothelial nitric oxide synthase biology Physiology business.industry Renal Hypertrophy medicine.disease biology.organism_classification Angiotensin II Muscle hypertrophy Endocrinology Fibrosis Enos Physiology (medical) Internal medicine mental disorders medicine biology.protein Secretion Human medicine Neuregulin 1 Cardiology and Cardiovascular Medicine business |
| Zdroj: | American journal of physiology: heart and circulatory physiology |
| ISSN: | 1522-1539 0363-6135 |
| DOI: | 10.1152/ajpheart.00914.2020 |
| Popis: | Endothelial cells (ECs) secrete different paracrine signals that modulate the function of adjacent cells; two examples of these paracrine signals are nitric oxide (NO) and neuregulin-1 (NRG1), a cardioprotective growth factor. Currently, it is undetermined whether one paracrine factor can compensate for the loss of another. Herein, we hypothesized that NRG1 can compensate for endothelial NO synthase (eNOS) deficiency. We characterized eNOS null and wild-type (WT) mice by cardiac ultrasound and histology and we determined circulating NRG1 levels. In a separate experiment, eight groups of mice were divided into four groups of eNOS null mice and WT mice; half of the mice received angiotensin II (ANG II) to induce a more severe phenotype. Mice were randomized to daily injections with NRG1 or vehicle for 28 days. eNOS deficiency increased NRG1 plasma levels, indicating that ECs increase their NRG1 expression when NO production is deleted. eNOS deficiency also increased blood pressure, lowered heart rate, induced cardiac fibrosis, and affected diastolic function. In eNOS null mice, ANG II administration not only increased cardiac fibrosis but also induced cardiac hypertrophy and renal fibrosis. NRG1 administration prevented cardiac and renal hypertrophy and fibrosis caused by ANG II infusion and eNOS deficiency. Moreover, Nrg1 expression in the myocardium is shown to be regulated by miR-134. This study indicates that administration of endothelium-derived NRG1 can compensate for eNOS deficiency in the heart and kidneys. NEW & NOTEWORTHY ECs compensate for eNOS deficiency by increasing the secretion of NRG1. NRG1 administration prevents cardiac and renal hypertrophy and fibrosis caused by ANG II infusion and eNOS deficiency. NRG1 expression is regulated by miR-134. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|